VIDEO: Preliminary IsKia trial results promising in multiple myeloma subgroup

ByErin Michael

Fact checked byMindy Valcarcel, MS

Healio spoke with Chakra Chaulagain, MD, about preliminary phase 3 results from the IsKia trial presented at ASH Annual Meeting and Exposition.

The trial assessed the safety and efficacy of isatuximab (Sarclisa, Sanofi)-carfilzomib-lenalidomide-dexamethasone (IsaKRd) in patients with newly diagnosed multiple myeloma compared with KRd alone.

“What the study showed was that the quadruplet therapy of isatuximab when combined with the triplet of KRd was associated with much higher [minimal residual disease (MRD)] negativity after the consolidation,” Chaulagain, director of the myeloma and amyloidosis program at Cleveland Clinic Florida, told Healio.

He said the findings showed that IsaKRd also provided benefits in patients with high-risk cytogenetic abnormalities, “which has been the group which has done historically poor, regardless of what kind of therapy you use.”

Chaulagain added that final data with a longer follow-up period is needed, but that updated results from the trial could be “practice changing.”

Reference:

Gay F, et al. Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2023; San Diego.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview

Disclosures: Chaulagain reports receiving research funding from Alexion, Bristol Myers Squibb and Janssen, and serving on the speaker’s bureau for Janssen and Sanofi.